Sugi Predict

Sugi Predict / Compounds / SCHEMBL3780335

SCHEMBL3780335

SCHEMBL3780335

NNC(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.67
▸ MPO P05164 2/20 0.67
▸ BLM P54132 2/20 0.67
▸ PMP22 Q01453 2/20 0.67
▸ KDM5A P29375 1/20 0.67
▸ GFER P55789 1/20 0.67
▸ HIF1A Q16665 1/20 0.67
▸ MAPT P10636 6/20 0.64
▸ KDM4E B2RXH2 4/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ L3MBTL1 Q9Y468 3/20 0.64
▸ OGG1 O15527 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ CYP2C19 P33261 2/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ ADORA3 P0DMS8 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ CYP2A6 P11509 1/20 0.58
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terephthalamide SCHEMBL2427917 0.91 MAPT (0.67) CYP3A4MPOBLMPMP22KDM5A
Terephthalamide SCHEMBL9565530 0.91 CYP3A4 (0.57) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL343630 0.89 MPO (0.80) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL18455085 0.89 PLA2G10 (0.66) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL2678949 0.89 MPO (0.80) CYP3A4MPOBLMPMP22KDM5A
Benzoic Acid Hydrazide SCHEMBL6009943 0.89 MAPT (0.70) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL18454411 0.88 MPO (0.53) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL28188923 0.87 MPO (0.76) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL18445445 0.86 CA2 (0.65) CYP3A4MPOBLMPMP22KDM5A
SCHEMBL752600 0.82 MPO (0.70) CYP3A4MPOBLMPMP22KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 — — US claimed
EP-2534132-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2012-12-19 — — EP claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 — — US claimed
US-12559455-B2 Compound as a UBR box domain ligand AUTOTAC INC. (KR) 2026-02-24 — — US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 — — US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 — — US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 — — US disclosed
WO-2023074936-A1 BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND 주식회사 오토텍바이오 2023-05-04 — — WO disclosed
EP-4144722-A1 COMPOUND AS UBR BOX DOMAIN LIGAND Autotac Inc. (KR) 2023-03-08 — — EP disclosed
CN-115715285-A Compounds as UBR box domain ligands 奧土择破利悟 2023-02-24 — — CN disclosed
CN-107847600-B Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors 豪夫迈·罗氏有限公司 2021-09-03 — — CN disclosed
US-20150211073-A1 MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST HOFFMANN-LA ROCHE INC. 2015-07-30 — — US disclosed
CN-104736614-A Fiber reinforced high modulus polymer composite with a reinforced interphase TORAY INDUSTRIES 2015-06-24 — — CN disclosed
CN-104718245-A High modulus fiber reinforced polymer composite TORAY INDUSTRIES 2015-06-17 — — CN disclosed
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 — — US disclosed
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 — — US disclosed
EP-2534132-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2012-12-19 — — EP disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 — — US disclosed
CN-101610761-A 1-amino methyl-L-phenyl-cyclohexane-derivant as the DDP-IV inhibitor NOVARTIS AG (CH) 2009-12-23 — — CN disclosed
US-20090111811-A1 1,2,4-TRIAZOLE CARBOXYLIC ACID DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111811-A1 1,2,4-TRIAZOLE CARBOXYLIC ACID DERIVATIVES AS MODULATORS OF MGLUR5 GRM5, GRIK5, GRM1 CYP3A4 2721/4885MPO 4612/4885BLM 4864/4885
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 CYP3A4 740/4885MPO 1306/4885BLM 3716/4885
US-20150211073-A1 MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST MDM2, TP53, TP53BP1 CYP3A4 3583/4885MPO 4862/4885BLM 1074/4885
US-20130012485-A1 ORGANIC COMPOUNDS DPP4, DPP3, DPP7 CYP3A4 13/4885MPO 61/4885BLM 3170/4885
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF CYP3A4 4471/4885MPO 3348/4885BLM 2008/4885
US-12559455-B2 Compound as a UBR box domain ligand UBR4, UBTF, UBQLN1 CYP3A4 4365/4885MPO 3389/4885BLM 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.